Mar 26, 2013 Cancer Headlines The other day, the - LIVESTRONG Website

There is a news topic touting still another progression in treating cancer just about any day. It is usually difficult to gauge which articles are reporting on small gains or slight variations on already popular solutions, and which statements mark the type major goals that mark future revolutions in cancer care. Last week, the headlines reported on an important advance that, as an oncologist, got me truly enthusiastic. aDeadly Leukemia Tamed by Fresh Immunity System Gene TherapyaaGene Therapy Spurs Leukemia HopeaaImmune-system therapy shows promise in adults with leukemiaa We have previously known of examples in which the immune protection system can be changed to attack it, with remarkable results as dangerous and recognize a patientas cancer. For example, patients with melanoma or kidney cancer could be treated with a harmful hormone named IL-2 which stimulates their own immune cells assured that some might then turn against cancer cells. A bone marrow transplant may be received by other patients from another individual in order to obtain a whole new immune protection system in hopes of fabricating a agraft-versus-tumora impact. When these remedies work, they could result in extraordinary and total answers, even in patients with chemotherapy-resistant cancers. But these immune solutions have become non-specific, often rarely leading to immune cells that successfully fight cancer, or leading to significant side effects from non-cancer fighting immune cells that harm the patientas normal cells. A fresh way for making better resistant cells was in the headlines the other day. A patientas own T-cells are removed, engineered to be active only against specific substances that are on the area of cancer cells, and re-infused to the patient. This process has, in early studies, been shown to be safe and impressive in the sorts of slow moving cancers (like chronic lymphocytic leukemia) for which the last generation of immune therapies were also often effective. The headline a week ago described on the use of these new, specific immune cells against a very intense and quick cancer, acute lymphoblastic leukemia. The treatment was very well accepted, and the advantages were amazing, with five out of five patients with resistant leukemia having a complete and rapid remission. New cancer therapies that are wise enough to attack cancer cells but in addition to sacrifice non-cancer cells from damage are in many ways the aHoly Graila of oncology. We have seen a revolution begin with the addition of monoclonal antibodies, molecularly targeted medicines, and now new approaches to engineer targeted T-cells. These will be the statements that someday might be labeled with aNobel Prizeaa

Link: Analyzing the nutritional value of a French toast